[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623171":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":30,"responsibleParty":52,"collaborators":18,"id":56,"slug":18,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":18,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":18,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","EXPERIMENTAL","Children with subclinical hypothyroidism who will receive L-thyroxine treatment in a dose of 2μg\u002Fkg\u002Fd (the smallest dose can be given) and the dose will be titrated every 4 weeks until a normal thyroid-stimulating hormone (TSH) level is maintained.",[13],"Drug: L-thyroxine",{"label":15,"type":16,"description":17,"interventionNames":18},"No treatment group","NO_INTERVENTION","Children with subclinical hypothyroidism who will receive no treatment.",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DRUG","L-thyroxine",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"Zeinab E Elshareef, MBBCH","CONTACT","00201001700194","zeinabibraheem26@gmail.com",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Tanta","El-Gharbia","31527","Egypt",{"type":38,"coordinates":39},"Point",[40,41],31.00192,30.78847,{"lat":41,"lon":40},[44,45,48,50],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},{"name":46,"role":47,"phone":18,"phoneExt":18,"email":18},"Doaa M EL Amrousy, MD","SUB_INVESTIGATOR",{"name":49,"role":47,"phone":18,"phoneExt":18,"email":18},"Dina E Abd EL hai, MD",{"name":51,"role":47,"phone":18,"phoneExt":18,"email":18},"Ola A Taha, MD",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Zeinab Ebraheem Amin Elshareef","Resident of Pediatrics, Tanta University, Tanta, Egypt.","100623171",false,"NCT07393165","Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","The Effect of Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","Inclusion Criteria:\n\n* Age from 4 to 15 years.\n* Both sexes.\n* Patients with stable elevated thyroid-stimulating hormone (TSH) ≥ 4.5 mIU\u002FL with normal free T4 and ft3 in different measurement 4 - 6 weeks apart.\n\nExclusion Criteria:\n\n* Overweight and obesity\n* Hypertension\n* Previous use of levothyroxine, antiepileptic drugs, or cardiac drugs within the last 6 months.\n* Arrhythmia.\n* Congenital or acquired heart disease\n* Liver or kidney disease\n* Hyperlipidemia\n* Diabetes\n* Infectious diseases\n* Respiratory diseases\n* Malignancies","ALL","4 Years","15 Years",{"count":66,"type":67},40,"ESTIMATED","INTERVENTIONAL",[70],"NA","This study aims to evaluate the effect of the treatment with levothyroxine on cardiac function in children with subclinical hypothyroidism.",[73,74,75,76],"Levothyroxine","Cardiac Function","Children","Subclinical Hypothyroidism","2026-01-31",{"date":79,"type":80},"2026-02-06","ACTUAL",{"date":82,"type":80},"2025-05-24",{"date":84,"type":67},"2026-05-01",{"name":5,"class":6},1]